By Brad Dunn — Officials have urged the Biden administration to prepare for the likelihood that the FDA will approve MDMA and psilocybin for breakthrough therapies within the next two years. In correspondence made public between the U.S. Dept of Health and Human Services and Rep. Madeleine Dean (D-Pa.), the administration indicated it is “exploring […]
By reMind Staff — Marking a victory for psychedelics advocates, the Drug Enforcement Agency announced Friday it was withdrawing its proposal to place five more tryptamines in schedule I of the Controlled Substances Act. The reversal follows intense pushback from psychedelics researchers, legal experts and the general public over the agency’s proposal in January to […]
By reMind Staff — The more you invested in psychedelics in the last year, the more likely you intend to increase those investments in the year ahead. That’s one of takeaways from Psychedelic Alpha’s inaugural Psychedelic Investor Pulse Survey, which polled 183 institutional, accredited and retail investors about their current attitudes toward the industry. When asked […]
By Brad Dunn — Mental health advocates in Colorado have gained enough support to add an initiative to the November ballot that would legalize certain psychedelic plants and fungi statewide. The Natural Medicine Colorado campaign collected enough signatures to support its effort to decriminalize ibogaine, psilocybin, DMT, and mescaline (excluding peyote) and to establish a regulatory […]
